Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 01:30PM GMT
Release Date Price: €5.96 (-3.20%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Everyone, my name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce the CEO of Karyopharm, Richard Paulson; and the CMO of Karyopharm, Reshma Rangwala; and also the CFO is joining us too, Mike Mason. Thanks so much for joining us today for the fireside discussion.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Thank you, Maury. Thanks for having us.

Questions & Answers

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Maybe to start off, for those who are new to the story, can you provide a 1-minute intro to Karyopharm and talk about key catalysts ahead in the next 6 to 12 months?

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Sure. I mean when you look at Karyopharm, we're a global company and a fully integrated commercial-stage company with a foundation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot